Treatment of Donors with Liposomal Alpha-Galactosylceramide Results in the In Vivo Expansion of Invariant Natural Killer T Cells and Reduced Incidence of Acute Graft Versus Host Disease

被引：0
|
作者：
Hirai, Toshihito
Simonetta, Federico
Baker, Jeanette
Maas-Bauer, Kristina
Turkoz, Musutafa
Alvarez, Maite
Mavers, Melissa
Negrin, Robert S.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1896
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15
    Hsu, Chien-Ya
    Chueh, Yu-Shan
    Kuo, Ming-Ling
    Lee, Pei-Tzu
    Hsiao, Hsiu-Shan
    Huang, Jing-Long
    Lin, Syh-Jae
    PLOS ONE, 2021, 16 (12):
  • [2] Activation of invariant natural killer T cells by alpha-galactosylceramide ameliorates doxorubicin-induced cardiotoxicity in mice
    Obata, Y.
    Ishimori, N.
    Saito, A.
    Kinugawa, S.
    Nakano, I.
    Kakutani, N.
    Yamanashi, K.
    Anzai, T.
    EUROPEAN HEART JOURNAL, 2019, 40 : 925 - 925
  • [3] Activation of invariant natural killer T cells by alpha-galactosylceramide ameliorates doxorubicin-induced cardiotoxicity in mice
    Obata, Yoshikuni
    Ishimori, Naoki
    Saito, Akimichi
    Kinugawa, Shintaro
    Yokota, Takashi
    Takada, Shingo
    Nakano, Ippei
    Kakutani, Naoya
    Yamanashi, Katsuma
    Anzai, Toshihisa
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 27 (19) : 2358 - 2361
  • [4] The use of ex vivo expanded human invariant natural killer T cells as a novel cell therapy to modulate graft versus host disease
    Im, J. S.
    He, H.
    Besra, G.
    Shpall, E. J.
    Porcelli, S.
    Molldrem, J. M.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 295 - 295
  • [5] Donor Treg expansion by liposomal α-galactosylceramide modulates Tfh cells and prevents sclerodermatous chronic graft-versus-host disease
    Sugiura, Hiroyuki
    Matsuoka, Ken-ichi
    Fukumi, Takuya
    Sumii, Yuichi
    Kondo, Takumi
    Ikegawa, Shuntaro
    Meguri, Yusuke
    Iwamoto, Miki
    Sando, Yasuhisa
    Nakamura, Makoto
    Toji, Tomohiro
    Ishii, Yasuyuki
    Maeda, Yoshinobu
    IMMUNITY INFLAMMATION AND DISEASE, 2021, 9 (03) : 721 - 733
  • [6] The Use of Ex Vivo Expanded Human Invariant Natural Killer T Cells as a Novel Cell Therapy to Modulate Graft-Versus-Host-Disease
    Im, Jin Seon
    He, Hong
    Rezvani, Katy
    Shpall, Elizabeth J.
    Ma, Qing
    Molldrem, Jeffrey
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S399 - S399
  • [7] Glycolipid antigen-specific invariant natural killer T cells for protection from graft-versus-host disease
    Schmid, H.
    Duerr-Stoerzer, S.
    Kettemann, F.
    Kanz, L.
    Salih, H.
    Savage, P.
    Schneidawind, C.
    Schneidawind, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 212 - 212
  • [8] Glykolipid antigen-specific invariant natural killer T cells for protection from graft-versus-host disease
    Schmid, H.
    Duerr-Stoerzer, S.
    Schneidawind, C.
    Kanz, L.
    Salih, H.
    Savage, P.
    Schneidawind, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 84 - 84
  • [9] Liposomal Alpha-Galactosylceramide Ameliorates Graft-Versus-Host Disease with Remaining Intensified GVL Gained By Dose-Reduction of Posttransplant Cyclophosphamaide after Haploidentical HSCT
    Nakamura, Makoto
    Matsuoka, Ken-Ichi
    Meguri, Yusuke
    Ikegawa, Shuntaro
    Sugiura, Hiroyuki
    Sando, Yasuhisa
    Iwamoto, Miki
    Asano, Takeru
    Ishii, Yasuyuki
    Maeda, Yoshinobu
    BLOOD, 2017, 130
  • [10] Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease
    Trujillo-Ocampo, Abel
    Cho, Hyun-Woo
    Herrmann, Amanda C.
    Ruiz-Vazquez, Wilfredo
    Thornton, Andrew B.
    He, Hong
    Li, Dan
    Qazilbashi, Mariam A.
    Ma, Qing
    Porcelli, Steven A.
    Shpall, Elizabeth J.
    Molldrem, Jeffrey
    Im, Jin S.
    CYTOTHERAPY, 2018, 20 (08) : 1089 - 1101
12345